Efficacy of Chinese Medicine Acupoint Application Combined with Montelukast on Children with Perennial Allergic Rhinitis:A Randomized Controlled Trial  

作　　者：LI You-jin ZONG Ming DING Li-feng RUI Xiao-qing MA Bei-yin QIN Li-ping 

机构地区：[1]Department of Otorhinolaryngology-Head and Neck Surgery,Shanghai Children's Medical Center,Shanghai Jiaotong University School of Medicine,Shanghai(200127),China [2]Department of Clinical Laboratory,Shanghai East Hospital,School of Medicine,Tong Ji University,Shanghai(200120),China [3]Department of Chinese Medicine,Shanghai Children's Medical Center,Shanghai Jiaotong University School of Medicine,Shanghai(200127),China [4]Department of Medical Genetics and Molecular Diagnostic Laboratory,Shanghai Children's Medical Center,Shanghai Jiaotong University School of Medicine,Shanghai(200127),China [5]Department of Chinese Medicine,Xinhua Hospital,Shanghai』aotong University School of Medicine,Shanghai(200090),China

出　　处：《Chinese Journal of Integrative Medicine》2020年第11期845-852,共8页中国结合医学杂志（英文版）

基　　金：Supported by the Medicine Leading Science and Technology Project of Shanghai Municipal Science and Technology Commission(No.15401933800)。

摘　　要：Objective To evaluate the efficacy of Chinese medicine acupoint application(CMAA)combined with Western medicine for perennial allergic rhinitis(PAR)in children.Methods In this prospective,parallel,randomized,placebo-controlled and single-blind trial from August to September,2017,180 children with PAR were randomly assigned to an integrative group(CMAA and Montelukast),CMAA group(CMAA and placebo tablet),or Montelukast group(placebo CMAA and Montelukast).Participants were applied with CMAA for 6 sessions over 2 weeks,and/or Montelukast Chewable Tablet orally once daily for 12 weeks.The changes in severity of symptoms were measured by Visual Analog Scale(VAS)and rhinitis control assessment test(RCAT)at 0,2,4 and 12 weeks of treatment.Blood samples were collected for serum interleukin-4,interferon gammaγand T helper type 1(Th1)/Th2 flow cytometric analysis at the time points of 0,4 and 12 weeks.Results Eight cases dropped out from the trial,3 in the integrative group,2 in the CMAA group and 3 in the Montelukast group.The VAS scores decreased significantly while the RCAT scores increased significantly in all three groups at 4 and 12 weeks compared with baseline(P<0.01 or P<0.05).The VAS scores were significantly lower while the RCAT scores were significantly higher in the integrative and CMAA groups than the Montelukast group at 2 and 4 weeks(P<0.01 or P<0.05).At 2,4 and 12 weeks,the scores of nasal congestion,sneezing,sleep problem,and rhinitis symptom control in the integrative and CMAA groups increased significantly compared with baseline(P<0.01 or P<0.05).The least percentages of Th2 and the most alleviated Th2 shift(highest Th1/Th2)were observed in the integrative group at 12 weeks compared with the other two groups(P<0.05).Conclusion The combination of CMAA with Montelukast might be more effective and appropriate than either option alone for children with PAR.(Registered at Chinese Clinical Trial Register,registration No.ChiCTR-IOR-17012434).

关 键 词：allergic rhinitis Chinese medicine acupoint application MONTELUKAST interferon gamma/interleukin-4 T helper type 1/T helper type 2 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]